The estimated Net Worth of Howard W Robin is at least $27 Million dollars as of 19 August 2024. Mr. Robin owns over 14,881 units of Nektar Therapeutics stock worth over $1,060,448 and over the last 18 years he sold NKTR stock worth over $16,026,107. In addition, he makes $9,939,250 as President, Chief Executive Officer und Director at Nektar Therapeutics.
Howard has made over 68 trades of the Nektar Therapeutics stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 14,881 units of NKTR stock worth $19,048 on 19 August 2024.
The largest trade he's ever made was exercising 600,000 units of Nektar Therapeutics stock on 24 November 2014 worth over $8,712,000. On average, Howard trades about 53,380 units every 39 days since 2007. As of 19 August 2024 he still owns at least 848,358 units of Nektar Therapeutics stock.
You can see the complete history of Mr. Robin stock trades at the bottom of the page.
Howard W. Robin is President, Chief Executive Officer, Director of the Company. Mr. Robin served as Chief Executive Officer, President and a director of Sirna Therapeutics, Inc., a biotechnology company, from July 2001 to November 2006 and from January 2001 to June 2001, served as their Chief Operating Officer, President and as a director. From 1991 to 2001, Mr. Robin was Corporate Vice President and General Manager at Berlex Laboratories, Inc. (Berlex), a pharmaceutical products company that is a subsidiary of Schering, AG, and from 1987 to 1991 he served as Vice President of Finance and Business Development and Chief Financial Officer of Berlex. From 1984 to 1987, Mr. Robin was Director of Business Planning and Development at Berlex. He was a Senior Associate with Arthur Andersen & Co. prior to joining Berlex. Mr. Robin serves as a director of the Biotechnology Industry Organization, the world’s largest biotechnology industry trade organization, and also serves as a director of BayBio, a non-profit trade association serving the Northern California life sciences community. He received his B.S. in Accounting and Finance from Fairleigh Dickinson University in 1974.
As the President, Chief Executive Officer und Director of Nektar Therapeutics, the total compensation of Howard Robin at Nektar Therapeutics is $9,939,250. There are 1 executives at Nektar Therapeutics getting paid more, with Jonathan Zalevsky having the highest compensation of $39,242,200.
Howard Robin is 67, he's been the President, Chief Executive Officer und Director of Nektar Therapeutics since 2007. There are 3 older and 15 younger executives at Nektar Therapeutics. The oldest executive at Nektar Therapeutics is Dr. Brian L. Kotzin, 72, who is the Sr. VP of Clinical Devel. & Head of Immunology.
Howard's mailing address filed with the SEC is C/O NEKTAR THERAPEUTICS, 455 MISSION BAY BLVD SOUTH, SAN FRANCISCO, CA, 94158.
Over the last 21 years, insiders at Nektar Therapeutics have traded over $57,608,493 worth of Nektar Therapeutics stock and bought 90,000 units worth $1,628,550 . The most active insiders traders include Howard W Robin, Gil M Labrucherie und John Nicholson. On average, Nektar Therapeutics executives and independent directors trade stock every 11 days with the average trade being worth of $36,648. The most recent stock trade was executed by Jonathan Zalevsky on 19 August 2024, trading 6,866 units of NKTR stock currently worth $8,788.
nektar therapeutics is a leading biopharmaceutical company developing a robust pipeline of novel therapeutics based on its advanced polymer conjugate chemistry technology platform. nektar also partners with the top biopharmaceutical companies to bring new products to market. to date, nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies.
Nektar Therapeutics executives and other stock owners filed with the SEC include: